February 23, 2021 -- Sirion Biotech has signed a license and collaboration agreement with Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors for the development of effective gene therapies.
The companies, along with AAV biology scientist Dirk Grimm, PhD, of Heidelberg University Hospital, will combine proprietary technology platforms to create next generation AAV vectors. The goal of the collaboration is to develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency.
Sanofi will leverage its expertise in virus-based vaccine and viral vector manufacturing, while Grimm will contribute AAV capsid evolution technology. Sirion will provide capabilities in AAV vector manufacturing.
Financial details of the collaboration were not disclosed.